Quick Facts: Uses of Ioril-10

• May be used to address: Premature labor
• May be considered for: Conditions related to poor blood flow to the brain (cerebral vascular insufficiency)
• May help manage: Disorders affecting the blood vessels outside of the heart and brain (peripheral vascular diseases)

---

Ioril-10 is a medication that may be prescribed by a healthcare professional to support the management of certain vascular and obstetrical conditions. Its approved uses include addressing symptoms related to premature labor.

For conditions involving the blood vessels, the medication may be considered for the management of peripheral vascular diseases such as arteriosclerosis obliterans and Buerger's disease. These conditions involve issues with circulation in the limbs. Ioril-10 may also be used to assist in the management of Raynaud's phenomenon, a condition characterized by reduced blood flow to the fingers and toes.

Additionally, the treatment may offer support for symptoms associated with cerebral vascular insufficiency, a condition where there is inadequate blood flow to the brain.

Eligibility Map: Who can and cannot use Ioril-10 — Official Regulatory Information

Eligibility Scope	Category	Official Regulatory Statement
Allowed Populations	Adult patients for labeled indications, including peripheral vascular disease and cerebral vascular insufficiency.
Contraindicated Groups	Use is strictly prohibited in patients with hypersensitivity to the drug, recent arterial hemorrhage, postpartum hemorrhage, severe anemia, known heart disease, eclampsia, severe pre-eclampsia, glaucoma, or a recent heart attack/stroke.
Age-Related Rules	Pediatric (Under 18): Safety and efficacy are not established for non-tocolytic uses. Geriatric: Use requires caution.
Restricted Use/Caution	Caution is required for patients with renal impairment, hepatic impairment, pre-existing hypotension, angina, or a history of hardening of the arteries.
Pregnancy/Lactation	Pregnancy: Permitted only when the potential benefit outweighs the risk. Lactation: No adequate studies exist; risks must be weighed carefully.

---

Eligibility Classifications

• Severity: Contraindicated (absolute non-eligibility), Not Established (lack of data), Use with Caution (conditional eligibility).
• Regulatory Basis: Eligibility is defined by labeling from authoritative national and intergovernmental health bodies.

---

Resulting Eligibility Structure

Official regulatory documents prohibit the use of Ioril-10 in populations with specific pre-existing conditions, particularly those involving bleeding or cardiac risk, and restrict use in patients with impaired organ function. This approach ensures that eligibility is strictly determined by documented safety profiles and established use, primarily limiting the medication to the adult population for its approved indications.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Ioril-10 (Isoxsuprine Hydrochloride) as classified in government regulatory labeling.

Pharmacodynamic Interaction Constraints

The primary documented interaction is categorized as pharmacodynamic, resulting from the combination of Ioril-10 with other agents that lower blood pressure. Co-administration with other vasodilators or anti-hypertensive drugs may lead to an additive hypotensive effect, which carries a regulatory-documented risk of hypotension.

Official Regulatory Status of Other Interactions

Interaction Type	Regulatory Status (Official Documentation)
Drug-Drug Contraindications	No known contraindications to oral use are stated when the medicine is administered at recommended levels.
Metabolic (CYP/Transporter)	No specific pharmacokinetic interactions that alter drug exposure via metabolic enzymes or drug transporters are formally documented in the regulatory label.
Food, Alcohol, or Herbal Products	No formal interaction patterns with food, alcohol, or herbal products that alter drug exposure or clearance are documented in the official regulatory label.
Timing Requirements	No mandatory time-separation rules are documented for any co-administered substance in the regulatory label.

This interaction profile is characterized by the absence of explicit metabolic or transporter interaction data, with regulatory constraints focusing strictly on the additive hypotensive risk inherent to the medicine's vasodilating classification.

Ioril-10 functions as an agonist by binding to the heterodimeric Interleukin-10 Receptor complex, comprised of the IL-10R1 and IL-10R2 subunits, which is expressed on various hematopoietic cells, including monocytes, macrophages, and T cells. This binding initiates signal transduction through the intracellular JAK-STAT pathway. Specifically, it induces the phosphorylation of Janus kinases (JAK1 and TYK2), which subsequently phosphorylate the receptor subunits.

This phosphorylation recruits and activates the cytoplasmic transcription factor STAT3 (Signal Transducer and Activator of Transcription 3). Activated STAT3 then translocates to the nucleus where it modulates gene expression. This molecular pathway leads to the upregulation of anti-inflammatory mediators, such as Suppressor of Cytokine Signaling 3 (SOCS3), which dampens further signal transduction. Concurrently, it inhibits the nuclear translocation and activity of pro-inflammatory transcription factors, such as NF-kB. The downstream intracellular cascade results in the decreased transcription and secretion of pro-inflammatory cytokines, including TNF-alpha and Interleukin-6 (IL-6), primarily by myeloid cells. The systemic physiological consequence is the modulation of immune and inflammatory cellular processes, limiting the release of specific pro-inflammatory signaling molecules.

Ioril-10 (Isoxsuprine) is administered using officially approved methods, including the oral route via 10 mg and 20 mg tablets, and a solution for injection for parenteral delivery. The injectable form, used for acute control, supports both intravenous and intramuscular delivery, with precise dosing rates determined by the supervising clinician based on the specific clinical scenario.

The standard adult oral regimen for routine management of vascular conditions typically falls within the 10 mg to 20 mg dose range per administration, scheduled for three or four times daily. This regimen establishes the pattern for long-term maintenance after initial symptoms are managed. The oral tablets may be taken with meals, milk, or antacids if necessary to mitigate potential stomach discomfort.

The official use protocol often involves transitioning a patient from the acute parenteral use to the scheduled oral regimen for maintenance. Procedurally, if a dose is missed and it is near the time for the next dose, instructions specify that the missed dose should be skipped, and the regular schedule resumed without taking a double amount. Regarding specific populations, the safety and effectiveness of Ioril-10 have not been established for use in pediatric patients.

Research evidence / Overview of studies for Ioril-10

---

Evidence for Use in Premature Labor and Threatened Abortion

Research has explored Ioril-10 in contexts related to conditions involving periods of heightened symptoms such as premature labor and threatened abortion. Research examined outcomes related to episodic or acute changes in contractions, including monitoring changes in the timing of delivery over short-term observation periods of 24 to 48 hours. The study populations typically included pregnant women between 24 and 37 weeks of gestation who were studied in the context of premature delivery.

The research base primarily consists of systematic reviews and meta-analyses that synthesize data from many older randomized controlled trials (RCTs). These findings describe patterns observed in the studies related to measured intervals of pregnancy continuation and measurements of uterine quiescence. Studies also monitored neonatal outcomes like birth weight and infant health following delivery.

However, the evidence is not uniform. The methodological quality of many of the aggregated primary studies evidence quality varies across studies, and many are described as small and dating from earlier periods. Regulatory records show that the formal application for this indication was not completed, impacting the scope of the available evidence base. Long-term effects are not fully established for both the mother and the infant, and there is limited information for long-term outcomes beyond the immediate post-treatment period.

---

Evidence for Use in Peripheral Vascular Conditions and Cerebral Insufficiency

This part will describe the research base for the medicine's use in conditions involving insufficient blood flow to the limbs and brain, focusing on the historical controlled studies and the physiological measures used to evaluate circulation and functional parameters.

The research was studied for its application in contexts related to conditions marked by functional limitations due to poor blood flow in the limbs (Peripheral Vascular Diseases) and the brain (Cerebral Vascular Insufficiency). Studies was evaluated in historical controlled studies, including some double-blind crossover trials where patients received both the study medicine and an inactive substance for comparison.

Data were not consistently reported across these earlier studies. Some research data show patterns related to measured changes in circulation. Conversely, one controlled study examined parameters of blood flow and functional ability, and data showed no change in those specific measurements. The official regulatory assessment indicated that the existing evidence structure did not meet the defined criteria for sufficiency. Therefore, comparative evidence is lacking from contemporary trials, and there is limited information for long-term outcomes.

Common questions about Ioril-10 (FAQ)

---

Q: Is Ioril-10 a new type of drug or has it been around for a while?

The active ingredient in Ioril-10, called Isoxsuprine, is classified among older, established medicines. Regulatory records indicate that this compound received its first official approvals in some international regions as far back as the 1960s.

---

Q: Is it safe to split or crush Ioril-10 tablets if I have trouble swallowing?

Official prescribing information for the Ioril-10 tablet does not contain instructions for altering or modifying the tablet form. This means the regulatory documentation does not contain formal instructions that allow for dividing, cutting, or crushing the tablets for administration.

---

Q: Does Ioril-10 have any known effects on a person's mood or emotional state?

Dizziness is listed as a documented adverse reaction in the official safety profile, under nervous system disorders. However, specific changes to mood or emotional state are not explicitly listed in the documented adverse reactions found in regulatory documents.

---

Q: Is Ioril-10 available as a generic medicine?

The active substance in Ioril-10, Isoxsuprine Hydrochloride, is a generic compound. This means the substance is produced to meet a specific quality standard, such as the United States Pharmacopeia (USP) designation.

---

Q: Can Ioril-10 affect the results of any laboratory tests?

Official regulatory documents do not provide specific warnings about known interferences with common laboratory test results. Specific information regarding interference with common laboratory test outcomes is not detailed in the official regulatory documents.

---

Q: Is Ioril-10 a controlled substance?

Based on official records from regulatory bodies, Ioril-10 is not classified as a controlled substance.

---

Q: Does Ioril-10 have any effects on appetite or taste perception?

The official safety profile for the medicine lists several gastrointestinal issues, including nausea and abdominal distress. However, changes in appetite or taste perception are not specifically documented within the list of official side effects.

---

Q: Can I drink alcohol while taking Ioril-10?

Official documentation states that no formal interaction pattern with alcohol is documented. However, the medicine is a vasodilator, a classification associated with the potential for hypotension (low blood pressure). Combining it with other substances that may lower blood pressure may increase the documented risk of this effect.

---

Q: Can I take Ioril-10 at the same time as my other medications?

Official regulatory documents state that no mandatory time-separation rules are documented for taking Ioril-10 with other co-administered substances. However, the known risk of an additive blood pressure lowering effect when taken with other vasodilators is noted in the regulatory documents.

---

Q: Can taking Ioril-10 cause me to feel dizzy or drowsy?

Dizziness is listed as a documented adverse reaction in official regulatory documents. However, drowsiness is not consistently included in the official safety profile documentation.

---

Q: What is the physical appearance of an Ioril-10 tablet?

Official documents describe the tablets primarily by their strength and listed ingredients. Because the physical appearance, such as color or shape, can vary between different manufacturers, it is not universally standardized in core regulatory labeling.

Official Storage Requirements

Ioril-10 (Isoxsuprine Hydrochloride) tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which should be kept tightly closed to protect the medicine.

Regulatory labeling mandates that the product be shielded from environmental factors: it must be stored away from excess heat and moisture, and it must not be frozen. Storage requirements also specify that the medicine must be protected from light.

Child Safety and Disposal

For safety, Ioril-10 must be stored out of sight and reach of children.

Official disposal instructions state that unused or expired medicine must not be disposed of through wastewater or released to the environment. Disposal must follow local, regional, or national regulations for approved waste disposal.